All‐cause mortality Time point of measurement: 2 months in 1 randomised study; 12 months in 3 randomised studies; 14 months in 1 non‐randomised study · adult survivors of the ICU, excluding those already in an existing follow‐up or rehabilitation programme
1 finding from 1 review
All‐cause mortality · Adults or children with overweight or obesity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · Adults or children with overweight or obesity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality: at 3 years · primary hepatocellular carcinoma
TACE followed by 3‐DCRT may leads to lower all‐cause mortality: at 3 years compared with TACE (low certainty).
1 finding from 1 review
All‐cause mortality ( · adults undergoing KA
1 finding from 1 review
All‐cause mortality · Patients with lung cancer
Annual low‐dose CT screening showed no clear difference in all‐cause mortality compared with annual chest x‐ray (high certainty).
1 finding from 1 review
All‐cause mortality ‐ planned time points · healthy adults
Low‐dose computed tomography (LDCT) screening probably leads to lower all‐cause mortality ‐ planned time points compared with no LDCT screening (moderate certainty).
1 finding from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).
1 finding from 1 review
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with no LMWH (low certainty).
1 finding from 1 review
All‐cause mortality (time‐to‐event) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality low risk of bias Mortality · patients with preventing hepatitis A.
The intervention showed no clear difference in all‐cause mortality low risk of bias Mortality (high certainty).
1 finding from 1 review
All‐cause mortality Up to 28 days following admission · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 28 days following admission compared with inactive Control (moderate certainty).
1 finding from 1 review
Anti‐cytokine, all‐cause mortality ‐ low risk of bias studies · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies leads to lower anti‐cytokine, all‐cause mortality ‐ low risk of bias studies compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality ‐ sensitivity analysis · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxin, all‐cause mortality ‐ low risk of bias studies compared with placebo (moderate certainty).
1 finding from 1 review
28‐Day all cause mortality (adult studies) · adult patients with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in low risk of bias adult studies, by type of polyclonal IVIG,… compared with placebo or no intervention (high certainty).
3 findings from 1 review
RR 0.97 [0.81, 1.15]
5 studies · 945 participants
High
RR 1.02 [0.84, 1.24]
3 studies · 683 participants
High
RR 0.82 [0.56, 1.19]
2 studies · 262 participants
Moderate
All‐cause mortality, neonates, standard polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in low risk of bias neonate studies, mortality all‐cause ‐ standard IVIG compared with placebo or no intervention (high certainty).
1 finding from 1 review